Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 3 | $1.93 | $1.93 | $1.93 |
Q2 2024 | 3 | $2.08 | $2.08 | $2.08 |
Q3 2024 | 2 | $2.05 | $2.06 | $2.05 |
Q4 2024 | 7 | $2.28 | $2.36 | $2.32 |
Q1 2025 | 7 | $2.31 | $2.47 | $2.40 |
Q2 2025 | 3 | $2.43 | $2.53 | $2.46 |
Q3 2025 | 6 | $2.38 | $2.48 | $2.42 |
Q4 2025 | 5 | $2.50 | $2.61 | $2.54 |
Q1 2026 | 4 | $2.56 | $2.67 | $2.60 |
Q2 2026 | 3 | $2.61 | $2.72 | $2.64 |
Q3 2026 | 2 | $2.55 | $2.66 | $2.59 |
Q4 2026 | 2 | $2.68 | $2.79 | $2.72 |
Q1 2027 | 2 | $2.72 | $2.84 | $2.76 |
Q2 2027 | 2 | $2.83 | $2.95 | $2.87 |
ResMed Inc. last posted its earnings results on Thursday, October 24th, 2024. The company reported $2.2 earnings per share for the quarter, topping analysts' consensus estimates of $2.04 by $0.16. The company had revenue of 1.22 B for the quarter and had revenue of 4.69 B for the year. ResMed Inc. has generated $7 earnings per share over the last year ($6.92 diluted earnings per share) and currently has a price-to-earnings ratio of 30.77. ResMed Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, January 22nd, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
10/24/2024 | Q1 2025 | $2.12 | $1.19 B | $1.22 B | ||
08/08/2024 | Q4 2024 | $1.99 | $1.22 B | $1.22 B | ||
04/25/2024 | Q3 2024 | $2.04 | $1.20 B | |||
01/24/2024 | Q2 2024 | $1.42 | $1.16 B | |||
10/26/2023 | Q1 2024 | $1.49 | $1.10 B | $963.04 M | ||
08/10/2023 | Q4 2023 | $1.56 | $1.14 B | $1.12 B | ||
04/27/2023 | Q3 2023 | $1.58 | $1.12 B | |||
01/26/2023 | Q2 2023 | $1.53 | $1.03 B | |||
10/27/2022 | Q1 2023 | $1.44 | $949.78 M | $950.29 M | ||
08/11/2022 | Q4 2022 | $1.33 | $910.56 M | $914.74 M | ||
04/28/2022 | Q3 2022 | $1.22 | $864.50 M | |||
01/27/2022 | Q2 2022 | $1.38 | $894.87 M | |||
10/28/2021 | Q1 2022 | $1.40 | $856.61 M | $904.02 M | ||
08/16/2021 | Q4 2021 | $1.34 | $799.54 M | $876.10 M | ||
04/29/2021 | Q3 2021 | -$0.54 | $768.77 M | |||
01/28/2021 | Q2 2021 | $1.24 | $800.01 M | |||
10/29/2020 | Q1 2021 | $1.23 | $710.06 M | $751.94 M | ||
08/12/2020 | Q4 2020 | $1.23 | $752.04 M | $770.34 M | ||
04/30/2020 | Q3 2020 | $1.13 | $769.46 M | |||
01/30/2020 | Q2 2020 | $1.11 | $736.16 M |
ResMed Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, January 22nd, 2025 based off last year's report dates.
In the previous quarter, ResMed Inc. (:RMD) reported $2.2 earnings per share (EPS) to beat the analysts' consensus estimate of $2.04 by $0.16.
The conference call for ResMed Inc.'s latest earnings report can be listened to online.
The conference call transcript for ResMed Inc.'s latest earnings report can be read online.
ResMed Inc. (:RMD) has a recorded annual revenue of $4.69 B.
ResMed Inc. (:RMD) has a recorded net income of $4.69 B. ResMed Inc. has generated $6.94 earnings per share over the last four quarters.
ResMed Inc. (:RMD) has a price-to-earnings ratio of 30.77 and price/earnings-to-growth ratio is 3.39.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED